Drug intelligence / Profile preview

LINC00173.v1 lentiviral vector

Development stage
Preclinical
Lead developer
Guangzhou Medical University
Modality
Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral, Intravenous
01

Overview

LINC00173.v1 lentiviral vector is an investigational gene therapy tool designed to overexpress the long non-coding RNA (lncRNA) LINC00173.v1. In the context of lung squamous cell carcinoma (SQC), LINC00173.v1 acts as an oncogenic driver by functioning as a competitive endogenous RNA (ceRNA). It specifically "sponges" or sequesters microRNA-511-5p (miR-511-5p), which normally suppresses the expression of Vascular Endothelial Growth Factor A (VEGFA). By inhibiting miR-511-5p, the vector leads to an upregulation of VEGFA, thereby promoting tumor angiogenesis and disease progression. This vector is primarily used in preclinical research to elucidate the molecular mechanisms of non-small-cell lung cancer (NSCLC) and to evaluate the LINC00173.v1/miR-511-5p/VEGFA axis as a potential therapeutic target.

Other names
LINC00173.v1-expressing lentivirusLINC-00173.v1-expressing lentivirusLINC 00173.v1-expressing lentivirusLV-LINC00173.v1LV-LINC-00173.v1LV-LINC 00173.v1Lentiviral-LINC00173.v1Lentiviral-LINC-00173.v1Lentiviral-LINC 00173.v1
02

Targets

Beyond the preview

Go deeper on LINC00173.v1 lentiviral vector.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LINC00173.v1 lentiviral vector.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call